In today’s recent session, 7.24 million shares of the Recursion Pharmaceuticals Inc (NASDAQ:RXRX) have been traded, and its beta is 0.89. Most recently the company’s share price was $4.42, and it changed around $0.34 or 8.23% from the last close, which brings the market valuation of the company to $1.79B. RXRX at last check was trading at a discount to its 52-week high of $12.36, offering almost -179.64% off that amount. The share price’s 52-week low was $3.79, which indicates that the recent value has risen by an impressive 14.25% since then. We note from Recursion Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 18.71 million shares, with the 3-month average coming to 21.04 million.
Recursion Pharmaceuticals Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.43. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 6 recommended RXRX as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information
Instantly RXRX has been showing a green trend so far today with a performance of 8.23% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 4.65 on recent trading dayincreased the stock’s daily price by 4.95%. The company’s shares are currently down -34.68% year-to-date, but still down -2.09% over the last five days. On the other hand, Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is -22.94% down in the 30-day period. We can see from the shorts that 93.12 million shares have been sold at a short interest cover period of 4.12 day(s).
The consensus price target as assigned by Wall Street analysts is $6, which translates to bulls needing to increase their stock price by 26.33% from its current value. Analyst projections state that RXRX is forecast to be at a low of $6 and a high of $6.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -35.28%. Recursion Pharmaceuticals Inc earnings are expected to increase by 15.09% in 2025, but the outlook is positive 19.85% per year for the next five years.
RXRX Dividends
Recursion Pharmaceuticals Inc’s next quarterly earnings report is expected to be released on 2025-May-04.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 5.07% of Recursion Pharmaceuticals Inc shares, and 75.94% of them are in the hands of institutional investors. The stock currently has a share float of 79.99%. Recursion Pharmaceuticals Inc stock is held by 444.0 institutions, with ARK INVESTMENT MANAGEMENT LLC being the largest institutional investor. By 2024-06-30, it held 11.6199% of the shares, which is about 28.14 million shares worth $211.07 million.
BAILLIE GIFFORD & CO, with 10.9787% or 26.59 million shares worth $199.42 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
ARK ETF Trust-ARK Innovation ETF and ARK ETF Trust-ARK Genomic Revolution ETF were the top two Mutual Funds as of Apr 30, 2025 . The former held 18.65 shares worth $82.26 million, making up 4.67% of all outstanding shares. On the other hand, ARK ETF Trust-ARK Genomic Revolution ETF held roughly 11.78 shares worth around $51.94 million, which represents about 2.95% of the total shares outstanding.
